Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib safety and pharmacokinetic study of BR-003 in spinal fusion surgery
NL-OMON53887Phase 1Recruiting
- Sponsor
- SentryX
- Start
- May 2023
- Modality
- Small Molecules, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BR003 and bupivacaine in postoperative pain (2 cohorts), sponsored by SentryX. Primary endpoint: Maximum plasma concentration of bupivacaine. Started May 2023; status: recruiting.
02
Drugs
BR003bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NL-OMON53887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53887.